Sanofi said the launch of new medicines and vaccines in other fields would help mitigate its dependence on Lantus, which accounts for nearly a fifth of sales

Sanofi, which sacked its chief executive three weeks ago, hopes to launch up to 18 new drugs by the end of 2020, with the potential to reap more than(...)

Christopher Viehbacher, ousted chief executive officer of French pharma group Sanofi. Photographer: Scott Eells/Bloomberg

Sanofi investors said former chief executive Chris Viehbacher, ousted today, paid the price for pushing too hard to make the French drugmaker more int(...)

Following on from Sunday’s stress test results, AIB was down by 5 per cent to 10 cents. Photograph:  Cyril Byrne

European shares rose yesterday, reversing the previous session’s dip as better-than-expected results from a number of blue-chips including pharma gro(...)

GlaxoSmithKline said last week it had received “very significant” indicative bids from private equity companies. Photographer: Chris Ratcliffe/Bloomberg

Private equity groups are exploring a $10 billion (€7.4 billion) plan to buy hundreds of older drug brands from GlaxoSmithKline (GSK) and Sanofi and m(...)

Property: its gains must be seen in the context of its recent fails

Who has the fairest fund of them all? If you’re looking for an investment with an element of risk, a fund is always an option for diversifying (...)

Ireland France Chamber of Commerce president  Jim Rice: “Over half of our members have witnessed higher levels of business activity and have increased staffing numbers, which can only be a positive signal.” Photograph: Eric Luke

A survey by the Ireland France Chamber of Commerce has found 69 per cent of its members expect to recruit more staff in the next three months, with(...)

France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe’s second(...)

French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the (...)

The market for MS drugs will grow to $20.2 billion a year by 2017, according to a 2011 report by GlobalData, a London- based research company.

Sanofi failed to win US regulatory approval for its multiple sclerosis drug Lemtrada, denting the company’s ambitions of capturing a larger share of t(...)

 Shire latched onto the rare disease drugs trend years before bigger rivals. Photographer: JB Reed/Bloomberg

London-listed Shire is buying ViroPharma for $4.2 billion its biggest deal yet to strengthen its portfolio of lucrative drugs to treat rare diseases, (...)